Australia's Rhythm Biosciences rises on accelerating commercialisation of cancer test

Rhythm Biosciences

18/03/2026 02:44

.

** Shares of Australia's Rhythm Biosciences RHY.AX rise 7.1% to A$0.225, set for their best session since March 11, if gains hold

** The medical diagnostics company accelerates the commercial rollout of its blood based ColoSTAT colorectal cancer test

** Says 4Cyte Pathology, a pathology services provider, has activated an initial network of 38 blood collection sites across states that enables clinician referral and patient access to ColoSTAT

** Immediate scale-up can now proceed directly with physicians, co adds

** RHY stock up 66.7%, year-to-date

 (Reporting by Shruti Agarwal in Bengaluru)

 ((Shruti.Agarwal@thomsonreuters.com))